We are live on ! Find out more
BEAM icon

Beam Therapeutics
BEAM

71 hedge funds and large institutions have $776M invested in Beam Therapeutics in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 7

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

59% more capital invested

Capital invested by funds: $489M → $776M (+$287M)

18% more funds holding

Funds holding: 60 → 71 (+11)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.87% less ownership

Funds ownership: 54.68% → 53.81% (-0.87%)

Holders
71
Holders Change
+11
Holders Change %
+18.33%
% of All Funds
1.46%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
19
Increased
25
Reduced
10
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$23.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.19M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.99M
4
Millennium Management
Millennium Management
New York
+$2.71M
5
BlackRock
BlackRock
New York
+$1.52M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$8.87M
2
Franklin Resources
Franklin Resources
California
-$5.41M
3
SFM
Sphera Funds Management
Israel
-$4.76M
4
FCM
Farallon Capital Management
California
-$3.06M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
SG Americas Securities
51
SG Americas Securities
New York
$192K +$148K +6,866 New
MIM
52
MetLife Investment Management
New Jersey
$185K – – –
Deutsche Bank
53
Deutsche Bank
Germany
$173K +$38.3K +1,776 +40%
PCM
54
Prelude Capital Management
New York
$157K +$121K +5,600 New
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
$131K – – –
Citigroup
56
Citigroup
New York
$111K +$9.46K +439 +12%
FHA
57
Flagship Harbor Advisors
Massachusetts
$79K – – –
Legal & General Group
58
Legal & General Group
United Kingdom
$77K +$17.8K +824 +43%
TRCT
59
Tower Research Capital (TRC)
New York
$73K +$56.3K +2,614 New
Canada Life
60
Canada Life
Manitoba, Canada
$39K +$30.3K +1,406 New
HIA
61
Harbor Investment Advisory
Maryland
$36K +$28K +1,300 New
Bank of Montreal
62
Bank of Montreal
Ontario, Canada
$30K +$21.1K +978 New
AIP
63
Ameritas Investment Partners
Nebraska
$29K – – –
EWM
64
Endurance Wealth Management
Rhode Island
$25K +$19.9K +925 New
BG
65
Bollard Group
Massachusetts
$23K +$17.4K +806 New
CAPTRUST Financial Advisors
66
CAPTRUST Financial Advisors
North Carolina
$20K +$15.1K +700 New
HI
67
Hudock Inc
Pennsylvania
$14K – – –
CSS
68
Cubist Systematic Strategies
Connecticut
$11K +$8.62K +400 New
Macquarie Group
69
Macquarie Group
Australia
$10K +$7.87K +365 New
VFA
70
Valeo Financial Advisors
Indiana
$5K +$3.88K +180 New
Royal Bank of Canada
71
Royal Bank of Canada
Ontario, Canada
$1K -$690 -32 -60%
Franklin Resources
72
Franklin Resources
California
– -$5.41M -300,509 Closed
SFM
73
Sphera Funds Management
Israel
– -$4.76M -264,681 Closed
FCM
74
Farallon Capital Management
California
– -$3.06M -170,164 Closed
ACH
75
ArrowMark Colorado Holdings
Colorado
– -$378K -21,000 Closed
1 2
3
4

BEAM Hedge Fund Activity: Q2 2020 in Review

71 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2020, worth a combined $776M — up 59% from $489M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new BEAM positions and 7 closed out — a net gain of 12 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was Vanguard Group, adding an estimated $23.1M. The largest seller was Victory Capital Management, cutting an estimated $8.87M.

  • 71 institutional investors held Beam Therapeutics (BEAM) as of Q2 2020, up from 60 in Q1 2020.
  • Funds reported $776M of Beam Therapeutics stock for Q2 2020, up 59% quarter-over-quarter.
  • 19 funds opened new Beam Therapeutics positions in Q2 2020 and 7 closed out, a net change of +12 holders.
  • The largest Beam Therapeutics buyer in Q2 2020 was Vanguard Group, an estimated $23.1M added.
  • The largest Beam Therapeutics seller in Q2 2020 was Victory Capital Management, an estimated $8.87M sold.

Based on aggregated 13F filings for Q2 2020.